NervGen Pharma Corp. (NGEN.V) Research

NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.

Market snapshot

Symbol
NGEN.V
Price
$5.15
Day change
+3.00%
Market cap
$407.9M
P/E ratio
-8.41x
52-week range
2.57-8.49
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cybin Inc. (CYBN.NE)
  • Medical Facilities Corporation (DR.TO)
  • Eupraxia Pharmaceuticals Inc. (EPRX.TO)
  • Fennec Pharmaceuticals Inc. (FRX.TO)
  • Helix BioPharma Corp. (HBP.TO)
  • HLS Therapeutics Inc. (HLS.TO)
  • Medicenna Therapeutics Corp. (MDNA.TO)
  • Satellos Bioscience Inc. (MSCL.TO)

Open NervGen Pharma Corp. (NGEN.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.